Atlas Trials

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

Clinical trial NCT02175433 · COMPLETED

Trial details

NCT number
NCT02175433
Sponsor
Astellas Pharma Global Development, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed Lymphoid MalignancyRefractory Lymphoid Malignancy
Start date
2014-10-14
Primary completion
2019-10-29
Enrollment
71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.